康莱特注射液联合贝伐珠单抗治疗晚期非小细胞肺癌的临床研究

目的 探讨康莱特注射液联合贝伐珠单抗治疗晚期非小细胞肺癌的疗效。方法 选取2020年10月—2023年6月河北省中医院收治的晚期非小细胞肺癌患者86例，采用随机数表法分为对照组(43例)和治疗组(43例)。对照组患者静脉滴注贝伐珠单抗注射液，首次化疗后给药，剂量15mg/kg,1次/3周，每次间隔3～5d再给药，共治疗3次。治疗组在对照组基础上静脉滴注康莱特注射液，200mL/次，1次/d，连续滴注21d,21d为1个周期，1个周期结束后间隔3～5d进入下1个周期，共治疗3个周期。观察两组患者临床疗效，比较治疗前后两组患者血清肿瘤标记物癌胚抗原、细胞角质蛋白19片段抗原21-1(CYFRA21-1)和糖类抗原125水平，免疫功能指标CD8⁺、CD3⁺、CD4⁺和CD4⁺/CD8⁺水平及不良反应情况。结果 治疗后，治疗组疾病控制率为88.37%，高于对照组的69.77%(P<0.05)。治疗后，两组患者癌胚抗原、CYFRA21-1、糖类抗原125水平、CD3⁺

Clinical study on Kanglaite Injection combined with bevacizumab in treatment of advanced non-small cell lung cancer

Objective To investigate the efficacy of Kanglaite Injection combined with bevacizumab in treatment of advanced non-small cell lung cancer. Methods Patients (86 cases) with advanced advanced non-small cell lung cancer in Hebei Provincial Hospital of Traditional Chinese Medicine from October 2020 to June 2023 were divided into control (43 cases) and treatment (43 cases) group according to random number table method. Patients in the control group were iv administered with Bevacizumab Injection, the dose was 15 mg/kg after the first chemotherapy, once every 3 weeks, each time at an interval of 3 to 5 days, they were treated for 3 times. Patients in the treatment group were iv administered with Kanglaite Injection on the basis of the control group, 200 mL/time, once daily for 21 d, after 21 d the interval was 3-5 d to enter the next 21 d, they were treated for 3 cycles. After treatment, the clinical evaluations were evaluated, the levels of tumor markers carcinoembryonic antigen, CYFRA21-1 and CA125, the levels of immune function indicators CD8⁺, CD3⁺, CD4⁺ and CD4⁺/CD8⁺, adverse reactions in two groups before and after treatment were compared. Results After treatment, the disease control rate in the treatment group was 88.37%, which was higher than that in the control group (69.77%, P < 0.05). After treatment, the levels of carcinoembryonic antigen, CYFRA21-1, carbohydrate antigen 125, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly decreased, and the level of these indexes in the treatment group was significantly lower than that in the control group (P < 0.05). During the treatment, the adverse reaction rate in the treatment group was 51.16%, which was significantly lower than that in the control group (72.09%, P < 0.05). Conclusion The combination of Kanglaite Injection and bevacizumab in treatment of advanced non-small cell lung cancer has a high disease control rate, can also improve the level of tumor markers and reduce the adverse reactions of chemotherapy and its adverse effects on immune function.